Related Experiment Video
Updated: Mar 29, 2026
05:39
Spontaneous Murine Model of Anaplastic Thyroid Cancer
Published on: February 3, 2023
2.4K
Local molecular analysis of indeterminate thyroid nodules
Mandeep S Gill1, Smriti Nayan2, Linda Kocovski3
1Division of Otolaryngology and Head and Neck Surgery, Department of Surgery, McMaster University, Hamilton, ON, Canada. mandeep.gill@medportal.ca.
Summary
Molecular analysis of mutations in BRAF, NRAS, KRAS, and HRAS shows promise for classifying indeterminate thyroid nodules. While not definitive, these genetic markers can aid in distinguishing benign from malignant thyroid tumors.
Area of Science:
- Endocrinology
- Oncology
- Molecular Diagnostics
Background:
- Thyroid nodules are prevalent, with most being benign.
- Accurate classification of indeterminate thyroid nodules is crucial for patient management.
- Molecular testing offers a potential tool to improve diagnostic accuracy.
Purpose of the Study:
- To evaluate the utility of analyzing BRAF, NRAS, KRAS, and HRAS mutations in fine-needle aspiration (FNA) samples.
- To determine if these molecular markers can help classify indeterminate thyroid nodules.
- To assess the sensitivity and specificity of these techniques compared to histopathology.
Main Methods:
- Retrospective analysis of 60 patients with indeterminate thyroid nodules undergoing surgery.
- Detection of BRAF, NRAS, KRAS, and HRAS mutations in FNA samples.
- Comparison of molecular results with final thyroidectomy specimen histopathology.
Main Results:
- 18 out of 60 patients had detectable mutations (10 malignant, 8 benign).
- Specific mutations demonstrated high specificity (up to 100%) but variable sensitivity (8.7% to 17.4%).
- BRAF, HRAS, KRAS, and NRAS mutations were identified in FNA samples.
Conclusions:
- Molecular analysis of BRAF, NRAS, KRAS, and HRAS mutations shows potential for classifying indeterminate thyroid nodules.
- These markers may serve as valuable 'rule-in' diagnostic tools.
- Further refinement of molecular techniques is needed for optimal clinical application.
